Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza B virus hemagglutinin protein (Victoria lineage)
- Molecular classification
- Glycoprotein, Viral protein, Hemagglutinin
01
Overview
The hemagglutinin (HA) protein of the Influenza B virus, specifically from the Victoria lineage, is a surface glycoprotein critical for viral entry into host cells. It binds to sialic acid receptors on host cells and mediates membrane fusion. As a major antigenic protein, it is a primary target for neutralizing antibodies and vaccine design. Victoria and Yamagata lineages differ antigenically, necessitating inclusion of both in quadrivalent vaccines. Victoria-lineage viruses may show preference for MUC5AC-positive cells and induce stronger interferon signaling compared to Yamagata.
- Other names
- HA (Victoria lineage)Hemagglutinin (Victoria lineage)
02
Mechanism of action
Vaccines: elicit neutralizing antibodies that block receptor binding or membrane fusion. Monoclonal antibodies: block receptor binding or membrane fusion.
03
Biological functions
Receptor bindingMembrane fusionViral entryImmune response elicitation
04
Disease associations
InfectionInfluenza
05
Safety considerations
Antigenic drift (necessitates annual vaccine updates)Potential for vaccine mismatch (if circulating strains differ significantly from vaccine strains)
06
Interacting drugs
Influenza vaccines
1 more in the full profile.
07
Biomarkers
HA antibody titers (vaccine efficacy)HA sequence (strain identification, vaccine matching)
Beyond the preview
Go deeper on Influenza B virus hemagglutinin protein (Victoria lineage).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza B virus hemagglutinin protein (Victoria lineage).